Genomic and Transcriptomic Sequencing of CAR-T-Treated Patients

Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies. Approximately half of patients with refractory large B-cell lymphomas achieve durable responses from CD19-targeting CAR-T treatment; however, failure mechanisms are identified in only a fraction of cases. Here we use next-generation sequencing technologies to characterize the genomic and transcriptomic features of CAR-T cells and tumors that influence therapeutic responses. Please see our submission to NCBI GEO (GSE273170) for additional data. ]]>
No patients were excluded from this study.]]>